A Versatile Microarray Platform for Capturing Rare Cells.
A Versatile Microarray Platform for Capturing Rare Cells.
复制标题
DOI：
10.1038/srep15342
复制
发表时间：
2015-10-23
影响因子：
4.6
通讯作者：
Fuchs H
中科院分区：
文献类型：
--
作者：
Brinkmann F;Hirtz M;Haller A;Gorges TM;Vellekoop MJ;Riethdorf S;Müller V;Pantel K;Fuchs H
对体液中极低频率发生的罕见事件的分析仍然具有挑战性。我们建立了一个通用的基于微阵列的平台，能够从大的背景群体中捕获单个靶细胞。作为用例，我们选择了检测循环肿瘤细胞（CTC）的挑战性应用-大约十亿个正常血细胞中的一个细胞。在与抗体混合物孵育后，在微流体芯片中的微阵列上提取靶细胞。我们平台的可访问性允许随后恢复目标以进行进一步分析。微阵列通过共定位促进排除假阳性捕获事件，从而允许在没有荧光标记的情况下进行检测。利用我们的平台分析癌症患者的血液样本达到并部分超过了黄金标准性能，证明了临床应用的可行性。临床研究人员可以自由选择抗体混合物，而无需改变芯片制造或孵育方案，允许虚拟任意靶向捕获物种，因此在生物医学科学中得到广泛应用。
Analyses of rare events occurring at extremely low frequencies in body fluids are still challenging. We established a versatile microarray-based platform able to capture single target cells from large background populations. As use case we chose the challenging application of detecting circulating tumor cells (CTCs) – about one cell in a billion normal blood cells. After incubation with an antibody cocktail, targeted cells are extracted on a microarray in a microfluidic chip. The accessibility of our platform allows for subsequent recovery of targets for further analysis. The microarray facilitates exclusion of false positive capture events by co-localization allowing for detection without fluorescent labelling. Analyzing blood samples from cancer patients with our platform reached and partly outreached gold standard performance, demonstrating feasibility for clinical application. Clinical researchers free choice of antibody cocktail without need for altered chip manufacturing or incubation protocol, allows virtual arbitrary targeting of capture species and therefore wide spread applications in biomedical sciences.